Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
24 Septembre 2021 - 01:30PM
Avicanna Inc. ("
Avicanna" or the
"
Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development, manufacturing
and commercialization of plant-derived cannabinoid-based
pharmaceuticals is pleased to announce that it has filed a
provisional patent application with the United States Patent and
Trademark Office, entitled "Methods for Reducing or Eliminating
Incidence of Seizures and Sudden Unexpected Death in Epilepsy", on
the use of a novel cannabinoid formulation (the
“
Formulation Candidate”).
The research findings originated from the
ongoing multi-level cannabinoid-based collaboration with leading
epilepsy researcher Dr. Peter Carlen at the world-renowned Krembil
Research Institute at the University Health Network (“UHN”).
Preliminary electrophysiological studies on seizure induced
wildtype mouse cortical slices determined that treatment with the
Formulation Candidate produced significant anti-convulsant effects
as compared to treatment with cannabidiol (“CBD”) or
tetrahydrocannabinol (“THC”) alone. These results, obtained in a
well-established in vitro model, suggest that, in addition to
anti-convulsant properties, the Formulation Candidate demonstrates
strong potential to treat patients diagnosed with intractable forms
of epilepsies and at risk of seizure-induced Sudden Unexpected
Death in Epilepsy (“SUDEP”). Further studies on the mechanism of
action of the cannabinoids in the Formulation Candidate confirmed
that the cannabinoids acted as selective 5-HT1A receptor agonists
similar to established 5-HT1A receptor agonists in seizure-like
events.
Aras Azadian, Chief Executive Officer of
Avicanna, stated: "Understanding the anti-convulsant properties of
our proprietary formulation in seizure disorders is important
particularly since this combination drug has potential to reduce
the likelihood of seizure-induced sudden death in epilepsy. The
exceptional research conducted by Dr. Carlen’s team with support
from our R&D team, and the resulting patent submission will be
a major driver for guiding our long-term drug and clinical
development plans, particularly since its in the area with an
existing FDA approved cannabinoid-based drug.”
Avicanna intends to conduct in vivo studies in
the coming months in order to formalize this provisional
application. If granted, this patent application will provide
Avicanna with protection on the use of the Formulation Candidate
within a specified ratio of cannabinoids, alone or in combination
with other anti-epileptic agents.
About Avicanna
Avicanna is a commercial stage Canadian
biopharmaceutical company and an established leader in cannabinoid
research, development, and evidence-based products for the global
consumer, medical, and pharmaceutical market segments. Avicanna
conducts its research in Canada including its R&D headquarters
in the Johnson & Johnson Innovation Centre, JLABS @ Toronto,
Canada, located in the MaRS Discovery District, and in
collaboration with leading Canadian academic and medical
institutions. Avicanna has established an industry leading
scientific platform including advanced R&D and clinical
development which has led to the commercialization of over twenty
products across four main market segments:
-
RHO Phyto™: these medical and wellness
products are an advanced line of pharmaceutical-grade cannabis
products containing varying ratios of CBD and THC. The product
portfolio contains a full formulary of products including oral,
sublingual, topical, and transdermal deliveries that have
controlled dosing, enhanced absorption and stability studies
supported by pre-clinical data. These products are developed using
pharmaceutical drug development processes and are supported with
pre-clinical data. The advanced formulary is marketed with
consumer, patient and medical community education and
training.
-
Pura H&W™: these registered, clinically
tested, cosmetic products include a portfolio of functional CBD
consumer derma-cosmetic and topical products.
-
Aureus™: as a part of Avicanna’s vertical
integration based out of Santa Marta, Colombia, its supply chain
business units are primarily dedicated to providing consistent
source of cannabinoid raw materials for Avicanna and its global
partner’s food, cosmetic, medical and pharmaceutical needs. Aureus
branded products are cultivated, extracted, and manufactured by
Avicanna’s subsidiaries in Colombia where they benefit from optimal
environmental conditions to produce cannabinoid active
pharmaceutical ingredients economically, organically, and
sustainably and include a range of CBD, THC and rare cannabinoids
such as CBG extracts and standardized seeds. Company is well
positioned to be a global supplier of cannabinoid raw materials
demand and has already successfully exported its products to over
10 countries in 4 continents.
-
Pharmaceutical pipeline: leveraging from the
company’s scientific platform, vertical integration, and real-world
evidence, Avicanna has established a pipeline of indication
specific cannabinoid-based drug candidates that are in various
stages of clinical development and commercialization. Avicanna’s
drug candidates are in pre-clinical stage and are dedicated to
providing solutions for unmet medical needs in the areas of
dermatology, chronic pain and various neurological disorders.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, call 1-647-243-5283, or contact IR representative
Iryna Zheliasko by email at iryna@chfir.com or by phone
at 416-868-1079 x 229.
The Company posts updates through videos from
the official company YouTube
channel https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains "forward-looking
information" within the meaning of applicable securities laws.
Forward-looking information contained in this press release may be
identified by the use of words such as, "may", "would", "could",
"will", "likely", "expect", "anticipate", "believe, "intend",
"plan", "forecast", "project", "estimate", "outlook" and other
similar expressions, and includes statements with respect to the
Company’s ability to generate data to support a final patent
application, the Company’s ability to continue its collaboration
with UHN, the Company’s ability to conduct further research on the
Formulation Candidate, the grant of any patent for the Formulation
Candidate. Forward-looking information is not a guarantee of future
performance and is based upon a number of estimates and assumptions
of management in light of management's experience and perception of
trends, current conditions and expected developments, as well as
other factors relevant in the circumstances, including assumptions
in respect of current and future market conditions, the current and
future regulatory environment; and the availability of licenses,
approvals and permits. Although the Company believes that the
expectations and assumptions on which such forward looking
information is based are reasonable, undue reliance should not be
placed on the forward looking information because the Company can
give no assurance that they will prove to be correct. Actual
results and developments may differ materially from those
contemplated by these statements. Forward-looking information is
subject to a variety of risks and uncertainties that could cause
actual events or results to differ materially from those projected
in the forward-looking information. Such risks and uncertainties
include, but are not limited to current and future market
conditions, including the market price of the common shares of the
Company, and the risk factors set out in the Company's annual
information form dated September 3, 2021 and final short form
prospectus dated November 27, 2020, filed with the Canadian
securities regulators and available under the Company's profile on
SEDAR at www.sedar.com . The statements in this press release are
made as of the date of this release. The Company disclaims any
intent or obligation to update any forward-looking information,
whether as a result of new information, future events or results or
otherwise, other than as required by applicable securities
laws.
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Avicanna (TSX:AVCN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024